GETI.B

210.7

-1.08%↓

CAMX

597.5

+2.4%↑

BIOAB

317.4

+3.52%↑

VITR

130

-1.59%↓

AMBEA

141.9

+2.09%↑

GETI.B

210.7

-1.08%↓

CAMX

597.5

+2.4%↑

BIOAB

317.4

+3.52%↑

VITR

130

-1.59%↓

AMBEA

141.9

+2.09%↑

GETI.B

210.7

-1.08%↓

CAMX

597.5

+2.4%↑

BIOAB

317.4

+3.52%↑

VITR

130

-1.59%↓

AMBEA

141.9

+2.09%↑

GETI.B

210.7

-1.08%↓

CAMX

597.5

+2.4%↑

BIOAB

317.4

+3.52%↑

VITR

130

-1.59%↓

AMBEA

141.9

+2.09%↑

GETI.B

210.7

-1.08%↓

CAMX

597.5

+2.4%↑

BIOAB

317.4

+3.52%↑

VITR

130

-1.59%↓

AMBEA

141.9

+2.09%↑

Elekta AB

Отворен

56.3 0.45

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

55.65

Максимум

56.55

Ключови измерители

By Trading Economics

Приходи

94M

230M

Продажби

424M

4.1B

P/E

Средно за сектора

74.079

76.798

EPS

0.64

Дивидентна доходност

4.32

Марж на печалбата

5.651

Служители

4,484

EBITDA

20M

529M

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

4.32%

2.37%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

4.9B

22B

Предишно отваряне

55.85

Предишно затваряне

56.3

Elekta AB Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

18.12.2025 г., 23:54 ч. UTC

Горещи акции

Stocks to Watch: Nike, Cassava Sciences, KB Home

18.12.2025 г., 23:51 ч. UTC

Печалби

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18.12.2025 г., 23:39 ч. UTC

Значими двигатели на пазара

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18.12.2025 г., 22:57 ч. UTC

Придобивния, сливания и поглъщания

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18.12.2025 г., 21:40 ч. UTC

Печалби

Nike Sales Tick Up, But China Weakness Persists

18.12.2025 г., 23:45 ч. UTC

Пазарно говорене

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18.12.2025 г., 23:37 ч. UTC

Пазарно говорене
Печалби

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18.12.2025 г., 23:36 ч. UTC

Пазарно говорене

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18.12.2025 г., 23:03 ч. UTC

Придобивния, сливания и поглъщания

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18.12.2025 г., 23:02 ч. UTC

Придобивния, сливания и поглъщания

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18.12.2025 г., 23:00 ч. UTC

Придобивния, сливания и поглъщания

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18.12.2025 г., 22:59 ч. UTC

Придобивния, сливания и поглъщания

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18.12.2025 г., 22:58 ч. UTC

Придобивния, сливания и поглъщания

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18.12.2025 г., 22:57 ч. UTC

Придобивния, сливания и поглъщания

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18.12.2025 г., 22:56 ч. UTC

Придобивния, сливания и поглъщания

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18.12.2025 г., 22:55 ч. UTC

Печалби

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18.12.2025 г., 21:59 ч. UTC

Печалби

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18.12.2025 г., 21:50 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

18.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

18.12.2025 г., 21:35 ч. UTC

Печалби

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18.12.2025 г., 21:31 ч. UTC

Печалби

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18.12.2025 г., 21:15 ч. UTC

Печалби

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18.12.2025 г., 21:15 ч. UTC

Печалби

Nike 2Q Greater China Rev Down 17% >NKE

18.12.2025 г., 21:15 ч. UTC

Печалби

Nike 2Q EPS 53c >NKE

18.12.2025 г., 21:15 ч. UTC

Печалби

Nike 2Q Apparel Rev $3.91B >NKE

18.12.2025 г., 21:15 ч. UTC

Печалби

Nike 2Q Equipment Rev $550M >NKE

18.12.2025 г., 21:15 ч. UTC

Печалби

Nike 2Q N Amer Rev $5.63B >NKE

18.12.2025 г., 21:15 ч. UTC

Печалби

Nike 2Q Footwear Rev $7.66B >NKE

18.12.2025 г., 21:15 ч. UTC

Печалби

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18.12.2025 г., 21:15 ч. UTC

Печалби

Nike 2Q Greater China Rev $1.42B >NKE

Сравнение с други в отрасъла

Ценова промяна

Elekta AB Прогноза

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Elekta AB

Elekta AB (publ), a medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. The company offers radiation therapy products, including Elekta Unity for real-time MR visualization; Elekta Versa HD, a brain metastases solution; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; and quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit; Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Leksell GammaPlan, a treatment planning and management software. In addition, the company offers Elekta ONE, a software suite of multiple Elekta solutions. Further, it provides brachytherapy products, including Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Elekta Xoft Axxent, and electronic brachytherapy systems; Elekta Geneva, an applicator for cervical cancer patients; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Venezia applicator that enables the oncologist to treat locally advanced cervical cancer. Additionally, the company offers neurosurgery products, such as Leksell Vantage Stereotactic System for intracranial neurosurgery. Furthermore, it provides Elekta Kaiku for personalized cancer care; and veterinary radiation therapy solutions. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
help-icon Live chat